KF
KERX

Krilogy Financial’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Krilogy Financial’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,000
Closed -$71K – 871
2017
Q3 		$71K Hold
10,000
– – 0.02% 300
2017
Q2 		$72K Buy
+10,000
New +$62.5K 0.02% 267

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Krilogy Financial's KERX Position: Q4 2017 in Review

Krilogy Financial sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 10,000 shares — an estimated $71K sold.

Krilogy Financial first reported a position in KERX in Q2 2017 and held it in 2 quarters. The position peaked at $72K in Q2 2017. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Krilogy Financial reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Krilogy Financial sold 10,000 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $71K.
  • Krilogy Financial first reported a position in Keryx Biopharmaceuticals Inc in Q2 2017 and held it in 2 quarters.
  • Krilogy Financial's Keryx Biopharmaceuticals Inc position peaked at $72K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Krilogy Financial's 13F filing for Q4 2017, filed 14 Feb 2018.